ASH 2023 | CD19 CAR-T therapy drives the expansion of clonal hematopoiesis and associated cytopenias in LBCL
Ash Alizadeh, MD, PhD, Stanford Comprehensive Cancer Center, Stanford, CA, discusses the findings of a study investigating the effect of CD19 CAR T-cell therapy on the incidence of prolonged cytopenias and associated infections. In a match-adjusted comparison, patients with large B-cell lymphoma (LBCL) receiving CD19 CAR-T had a higher risk of severe infection and death compared to patients undergoing autologous stem cell transplantation (autoSCT). Profiling of cell-free DNA (cfDNA) before and after treatment revealed that patients with evidence of clonal hematopoiesis of indeterminate potential (CHIP) were more likely to develop cytopenia following CAR-T, and the conclusion was made that CD19 CAR-T therapy drove the expansion of clonal hematopoiesis and associated cytopenias in these patients. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
